For development and commercialisation of a Dual PI3K-delta gamma Inhibitor
Alembic Pharmaceuticals announced that its associate company, Rhizen Pharmaceuticals SA has entered into an exclusive worldwide license agreement with Novartis for the development and commercialisation of Rhizen's, inhaled dual PI3K-delta gamma inhibitor and its closely related compounds for various indications.Under the terms of the agreement, Rhizen will receive an unfront payment and is eligible to receive development, regulatory and sales milestones payments. In addition, Rhizen is also eligible to receive tiered royalties on annual net sales.
The lead compound is a novel, potent and selective dual PI3K-delta gamma inhibitor with demonstrated anti-inflammatory and immune-modulatory activity in pre-clinical systems and models representative of respiratory diseases.
Powered by Capital Market - Live News
